fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-01-11 I Launch Summit (UK) BioMarin Pharmaceuticals   SMT C1100 (small molecule utrophin upregulator) Duchenne muscular dystrophy   See details
2010-01-08 I Result Funxional Therapeutics (UK)   FX125L - orally available small molecule - Broad Spectrum Chemokine Inhibitors (BSCIs) inflammatory diseases USA See details
2010-01-08 III Launch Plexxikon (USA) Roche (Switzerland) PLX4032 (RG7204 - oral and highly targeted drug designed to inhibit the BRAF cancer-causing mutation) The product has been discovered by Plexxikon. It is co-developed under a 2006 license and collaboration agreement with Roche. In parallel, Plexxikon and Roche Molecular Systems are also co-developing a DNA-based companion diagnostic to identify patients whose tumors carry the BRAF mutation. metastatic melanoma USA, Australia, Europe and Canada See details
2010-01-06 II Launch TopoTarget (Denmark)   Belinostat This histone deacetylase (HDAC) inhibitor is associated with carboplatin. platinum-resistant ovarian cancer, fallopian tube, or primary peritoneal cancer USA See details
2010-01-04 II Launch Intercell (Austria)   Travelers' Diarrhea (TD) Vaccine Patch The TD vaccine system consists of a self-adhesive patch containing the vaccine antigen, the LT (heat-labile toxin) from E. coli, and a single-use device used to prepare the skin at the site of patch administration, the Skin Preparation System (SPS). Travelers' Diarrhea UK, Germany See details
2010-01-04 I-II Result Immutep (France)   ImmuFact® - IMP321 (T cell immunostimulatory agent) ImmuFact® is an antigen-presenting cell (APC) agonist and is a soluble form of the LAG-3 ("lymphocyte activation gene-3") T cell surface receptor that binds, with high affinity, to MHC ("major histocompatibility complex") class II molecules on APC such as monocytes and dendritic cells. metastatic breast cancer France See details
2009-12-29 III Launch Intercell (Austria)   Ixiaro®/Jespect® Japanese Encephalitis USA, Europe and Australia See details
2009-12-23 III Launch LifeCycle Pharma (Denmark)   LCP-Tacro® (once-daily tablet version of tacrolimus) de novo kidney transplant recipients USA and Europe See details
2009-12-22 I-II Result Ablynx (Belgium)   ALX-0081 (Nanobody® targeting von Willebrand factor) patients with stable angina undergoing percutaneous coronary intervention (PCI)   See details
2009-12-21 I-II Launch   UCB (Belgium) certolizumab pegol - pegylated fab’ fragment of a humanized anti-TNF alpha monoclonal antibody Crohn’s disease International and multicenter trial See details
2009-12-21 III Result Actelion (Switzerland) GSK (UK) almorexant (dual orexin receptor antagonist) primary insomnia   See details
2009-12-18 IIa Launch Flamel Technologies (France)   IFN-Alpha-2b XL (interferon alpha-2b XL - controlled release of unmodified interferon alpha-2b) chronic hepatitis C France See details
2009-12-17 III Launch   Boehringer Ingelheim (Germany) BIBF1120 (Vargatef®) This oral anti-angiogenic agent works by simultaneously inhibiting three receptors involved in angiogenesis. ovarian cancer   See details
2009-12-17 III Result   Roche (Switzerland) taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights. diabetes   See details
2009-12-16 II Result Antisoma (UK)   AS1411 (aptamer binding to nucleolin, protein which is found on the surface of cancer cells) metastatic renal cell carcinoma (kidney cancer)   See details
[<<]      «      4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14      »      [57]